OMEROS CORP (OMER) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, OMEROS CORP's filing signal turned positive.

Omeros Corporation is a commercial-stage biotechnology company focused on developing therapeutics for complement-mediated diseases, cancers, and addictive or compulsive disorders. Its lead commercial product, YARTEMLEA (narsoplimab-wuug), is the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), receiving FDA approval in December 2025 and commencing U.S. sales in January 2026. The company also has a significant partnered program with Novo Nordisk for zaltenibart, a MASP-3 inhibitor, which Omeros licensed in November 2025, potentially earning up to $1.8 billion in milestones and royalties. Omeros' pipeline includes other complement inhibitors like OMS1029, a PDE7 inhibitor program (OMS527) for addiction and movement disorders, and an oncology program (OncotoX-AML). The company operates globally, with its primary executive offices in Seattle, Washington.

Primary revenue drivers include sales of its commercial product, YARTEMLEA, and potential milestone and royalty payments from its partnered zaltenibart program with Novo Nordisk. The company also retains rights to its MASP-3 small-molecule program.